Jeito is a next-generation fund with a patient benefit driven approach, that focuses both on financing ground-breaking medical innovation and promoting positive societal impact. We empower and support entrepreneurs through our expert, integrated, multi-talented team.
Jeito Capital is based in Paris with a presence in Europe and the United States.
Follow us to get our latest news & job offers.
Jeito Capital is based in Paris with a presence in Europe and the United States.
Follow us to get our latest news & job offers.
Location: France, Ile-de-France, Paris
Employees: 11-50
Founded date: 2017
Investment Type: Venture Capital
Investment Stage: Series A; Series B; Series C; Series D
Portfolio 23
| Date | Name | Website | Total Raised | Location |
| 13.03.2026 | Alveus The... | alveustx.com | - | Denmark |
| 26.10.2025 | Odyssey Th... | odysseytx.com | $487M | United Sta... |
| 10.06.2025 | Augustine ... | augustinetx.com | $102.34M | Belgium, E... |
| 10.06.2025 | AZAFAROS B... | azafaros.com | $175.64M | Netherland... |
| 10.06.2025 | ReproNovo | repronovo.com | $65M | Switzerlan... |
| 31.03.2025 | Callio The... | calliotx.com | - | - |
| 27.03.2025 | Aviceda Th... | avicedarx.com | $207.5M | United Sta... |
| 27.03.2025 | XyloCor Th... | xylocor.com | $126.4M | - |
| 09.02.2024 | Advesya | advesya.com | - | - |
| 01.11.2023 | Corteria P... | corteriapharma.com | $69.6M | France, Il... |
Show more
Persons 20
| Date | First Name | Last Name | Title | Location | |||
| - | Julie | - | Investor R... | - | - | - | |
| - | Mehdi | - | Partner | - | - | - | |
| - | Karin | - | Chief Regu... | - | - | - | |
| - | Noémie | - | Associate | - | - | - | |
| - | Alain | - | Chief Fina... | - | - | - | |
| - | Charlotte | - | Senior Leg... | - | - | - | |
| - | Benjamin | - | Finance Di... | - | - | - | |
| - | Elsa | - | Finance Di... | - | - | - | |
| - | Ksenija | - | General Pa... | - | - | - | |
| - | Henri | - | Legal Coun... | - | - | - |
Show more
Mentions in press and media 28
| Date | Title | Description |
| 22.05.2025 | ReproNovo's $65 Million Leap: A New Dawn for Reproductive Health | In a world where fertility rates are slipping like sand through fingers, ReproNovo emerges as a beacon of hope. This Swiss HealthTech startup, founded in 2021, has just secured $65 million in Series A financing. The funding round, led by Je... |
| 21.05.2025 | ReproNovo raises USD65 million to advance Phase II clinical trials | ReproNovo, founded in 2021, is developing novel approaches to address critical gaps in reproductive medicine and women’s health, including male and female infertility as well as uterine health. The company, led by a team with expertise in ... |
| 07.01.2025 | Jeito Capital's Bold Moves in Biopharma: A Strategic Investment Landscape | In the world of biopharma, where innovation is the lifeblood, Jeito Capital is making waves. This Paris-based private equity fund is not just dipping its toes; it’s diving deep into the ocean of clinical-stage biotech. With a recent investm... |
| 07.01.2025 | French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics | Paris-based Jeito Capital, a PE fund focused on biopharma innovation, has furthered its position as a player in global healthcare investment with two major contributions to clinical-stage biotech companies Aviceda Therapeutics and XyloCor T... |
| 13.11.2024 | Alentis Therapeutics Secures $181.4 Million to Pioneer Cancer Treatments | In a bold move to reshape cancer treatment, Alentis Therapeutics has successfully raised $181.4 million in an oversubscribed Series D funding round. This infusion of capital, led by OrbiMed and co-led by Novo Holdings and Jeito Capital, sig... |
| 12.11.2024 | Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors | Jeito Capital co-leads €164.5 million1 ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 (CLDN1) ADCs in solid tumors Building on its co-lead investments in Alentis ... |
| 12.11.2024 | Alentis Therapeutics raises $181.4 million in oversubscribed series D round | Normal 0 false false false EN-GB X-NONE AR-SA Besides OrbiMed, Novo Holdings and Jeito Capital, Alentis Therapeutics’ series D round saw the participation of new investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Hea... |
| 29.05.2024 | Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion | - |
| 07.09.2023 | Corteria Pharmaceuticals Announces a €65M Financing to Advance Transformational Medicines in Cardiovascular Diseases | Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M) Series A co-led by US ... |
| 13.04.2023 | Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis | - |
Show more